AGP Picks
View all

Xenpozyme market gains traction as rare disease treatment evolves

3 hours ago
Xenpozyme market gains traction as rare disease treatment evolves
By AI, Created 00:30 UTC, Nov 20, 2026, AGP -

The Business Research Company says the Xenpozyme market is expanding as rare disease diagnosis, personalized medicine and healthcare infrastructure improve. North America held the largest share in 2025, while the report points to broader growth across enzyme replacement therapy and rare disease pipelines.

Why it matters: - Xenpozyme targets acid sphingomyelinase deficiency, a rare genetic disorder that includes Niemann-Pick disease types A, A/B and B. - The market is tied to broader demand for rare disease therapies, better diagnosis and more specialized biologics. - Growth in this category can improve access to treatment for patients with limited options.

What happened: - The Business Research Company released a Xenpozyme market report focused on market trends, segment details and business strategies. - The report says North America held the largest share of the Xenpozyme market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Xenpozyme is an enzyme replacement therapy designed to replace deficient acid sphingomyelinase using recombinant human acid sphingomyelinase, or rhASM. - The therapy helps break down sphingomyelin, a lipid that can accumulate in organs and contribute to disease progression. - Historic market growth has been driven by greater awareness of Niemann-Pick disease, recombinant protein manufacturing progress, orphan drug development and more clinical trial activity in rare diseases. - Better access to diagnostic testing has also supported expansion. - The report expects future growth from rising investment in rare disease pipelines, broader adoption of personalized medicine, expanded newborn screening, wider global access to specialty biologics and enzyme stabilization advances. - The report highlights increased use of enzyme replacement therapies, more rare disease development, higher recombinant enzyme production capacity, earlier diagnosis of lysosomal diseases and improved management of acid sphingomyelinase deficiency as key forecast trends. - Genetic disorders are a central growth driver for the market. - The Cystic Fibrosis Trust reported in October 2024 that registered cystic fibrosis patients in the UK increased from 11,148 in 2022 to 11,318 in 2023. - Personalized medicine is another driver. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Healthcare infrastructure growth is also supporting the market. - The Centers for Medicare & Medicaid Services reported in December 2024 that U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The report frames Xenpozyme as part of a larger shift toward precision treatment for rare genetic diseases. - Diagnostics matter as much as drug development because earlier identification expands the treatable patient pool. - North America’s lead suggests the region has stronger diagnosis, reimbursement or treatment access than other markets, though the report does not break out the reason.

What's next: - The report expects continued growth as orphan drug pipelines, newborn screening and specialty biologic access expand. - Market development will likely depend on how quickly healthcare systems adopt earlier diagnosis and broader rare disease treatment programs. - The Business Research Company directs readers to its website and social channels for more information.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

STEM News Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

STEM News Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.